IDiyas

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Laurie B Schenkel

USPTO Granted Patents = 25 

 

Average Co-Inventor Count = 5.9

ph-index = 6

Forward Citations = 112(Granted Patents)


Location History:

  • Boston, MA (US) (2010 - 2017)
  • Somerville, MA (US) (2020 - 2024)
  • Cambridge, MA (US) (2022 - 2024)

Company Filing History:

goldMedal11 out of 1,970 
 
Amgen Inc.
 patents
silverMedal10 out of 11 
 
Ribon Therapeutics, Inc.
 patents
bronzeMedal3 out of 1,535 
 
Boehringer Ingelheim International Gmbh
 patents
4. 1 out of 124 
 
Teijin Pharma Limited
 patents

Years Active: 2010-2025

where 'Filed Patents' based on already Granted Patents

25 patents (USPTO):
1. 12398146 - Heterobicyclic amides as inhibitors of CD38 (2025-08-26),
2. 12371421 - Solid forms of a PARP7 inhibitor (2025-07-29),
3. 11987584 - Heterobicyclic amides as inhibitors of CD38 (2024-05-21),
4. 11958837 - Quinazolinones as PARP14 inhibitors (2024-04-16),
5. 11952377 - Quinolines and azaquinolines as inhibitors of CD38 (2024-04-09),
6. 11566020 - Pyridazinones as PARP7 inhibitors (2023-01-31),
7. 11535621 - Heterobicyclic amides as inhibitors of CD38 (2022-12-27),
8. 11332459 - Benzimidazole derivatives and their uses (2022-05-17),
9. 11293927 - Screening methods for PARP modulators (2022-04-05),
10. 11014913 - Pyridazinones as PARP7 inhibitors (2021-05-25),
11. 11008308 - Quinazolinones as PARP14 inhibitors (2021-05-18),
12. 10870641 - Pyridazinones as PARP7 inhibitors (2020-12-22),
13. 10562891 - Quinazolinones as PARP14 inhibitors (2020-02-18),
14. 10550105 - Pyridazinones as PARP7 inhibitors (2020-02-04),
15. 9663508 - Biaryl acyl-sulfonamide compounds as sodium channel inhibitors (2017-05-30),

Title: Inventor Spotlight: Laurie B Schenkel

Introduction:

Laurie B Schenkel, a brilliant inventor based in Cambridge, MA (US), has made significant contributions to the fields of cancer treatment and inflammatory disease management. With an impressive portfolio of 22 patents, Laurie is recognized for her innovative approach to developing compounds that inhibit key enzymes involved in disease progression.

Latest Patents:

1. Quinazolinones as PARP14 inhibitors - Laurie's groundbreaking invention involves quinazolinones and related compounds that act as potent inhibitors of PARP14. These compounds demonstrate utility in the treatment of cancer and inflammatory diseases, showcasing Laurie's commitment to advancing therapeutic solutions.

2. Quinolines and azaquinolines as inhibitors of CD38 - In another cutting-edge invention, Laurie introduces bicyclic heterocycle compounds that serve as inhibitors of CD38. These compounds hold promise in addressing disease mechanisms, highlighting Laurie's expertise in drug development.

Career Highlights:

Laurie B Schenkel's remarkable career includes notable tenures at renowned companies such as Amgen Inc. and Ribon Therapeutics, Inc. Her innovative mindset and dedication to scientific advancement have driven breakthroughs in the pharmaceutical industry, setting her apart as a visionary inventor.

Collaborations:

Throughout her career, Laurie has collaborated with esteemed professionals in the field, including coworkers Melissa Marie Vasbinder and Kevin Wayne Kuntz. These collaborations have fostered a dynamic exchange of ideas, leading to impactful innovations that have the potential to transform healthcare practices.

Conclusion:

In conclusion, Laurie B Schenkel stands as a trailblazing inventor with a passion for developing novel therapeutic solutions. Her exceptional patent portfolio and collaborative spirit reflect a commitment to pushing boundaries and shaping the future of medicine. Laurie's contributions continue to inspire and pave the way for groundbreaking advancements in disease treatment and management.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…